Bioresorbable scaffolds: Focus on vascular response and long-term safety

Panminerva Medica

Volumn 57, Issue 1, 2015, Pages 1-13

  Scalonel, G ^a   Brugaletta, S ^a   Gomez, O ^a   Otsuki, S ^a   Sabate, M ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Cardiology; Tissue scaffolds; Treatment outcome

Indexed keywords

BIOCOMPATIBLE COATED MATERIAL; CARDIOVASCULAR AGENT;

ADVERSE EFFECTS; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; CORONARY THROMBOSIS; DEVICES; DRUG ELUTING STENT; HEART CATHETER; HUMAN; MORTALITY; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PROSTHESIS DESIGN; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME;

CARDIAC CATHETERS; CARDIOVASCULAR AGENTS; COATED MATERIALS, BIOCOMPATIBLE; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; CORONARY THROMBOSIS; DRUG-ELUTING STENTS; HUMANS; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PROSTHESIS DESIGN; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84989788923     PISSN: 00310808     EISSN: 18271898     Source Type: Journal    
DOI: None     Document Type: Article

References (90)

1. Gruentzig AR, King SB 3rd, Schlumpf M, Siegenthaler W. Longterm follow-up after percutaneous transluminal coronary angioplasty: The early Zurich experience. N Engl J Med 1987;316: 1127-32
2. Serruys PW, Luijten HE, Beatt KJ, Geuskens R, de Feyter PJ, vanden Brand M et al. Incidence of restenosis after successful coronary angioplasty: A time-related phenomenon: A quantitative angiographic study in 342 consecutive patients at 1, 2, 3, and 4 months. Circulation 1988;77:361-71
3. Di Mario C, Gil R, Camenzind E, Ozaki Y, von Birgelen C, Umans V et al. Quantitative assessment with intracoronary ultrasound of the mechanisms of restenosis after percutaneous trans-luminal coronary angioplasty and directional coronary atherectomy. Am J Cardiol 1995;75:772-7
4. Mintz GS, Popma JJ, Pichard AD, Kent KM, Satler LF, Wong C et al. Arterial remodeling after coronary angioplasty: A serial intravascular ultrasound study. Circulation 1996;94:35-43
5. Rodriguez AE, Santaera O, Larribau M, Fernandez M, Sarmiento R, Perez Balino et al. Coronary stenting decreases restenosis in lesions with early loss in luminal diameter 24 hours after successful PTCA. Circulation 1995;91:1397-402
6. Clowes AW, Reidy MA, Clowes MM. Kinetics of cellular proliferation after arterial injury. I: Smooth muscle growth in the absence of endothelium. Lab Invest 1983;49:327-33
7. Nobuyoshi M, Kimura T, Ohishi H, Horiuchi H, Nosaka H, Hamasaki N et al. Restenosis after percutaneous transluminal coronary angioplasty: Pathologic observations in 20 patients. J Am Coll Cardiol 1991;17:433-9
8. Garratt KN, Edwards WD, Kaufmann UP, Vlietstra RE, Holmes DR Jr. Differential histopathology of primary atherosclerotic and restenotic lesions in coronary arteries and saphenous vein bypass grafts: Analysis of tissue obtained from 73 patients by directional atherectomy. J Am Coll Cardiol 1991;17:442-8
9. Ormiston JA, Stewart FM, Roche AH, Webber BJ, Whitlock RM, Webster MW. Late regression of the dilated site after coronary angioplasty: A 5-year quantitative angiographic study. Circulation 1997;96:468-74
10. Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease: Benestent Study Group. N Engl J Med 1994;331:489-95
11. Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med 1994;331:496-501
12. Sousa JE, Costa MA, Abizaid AC, Rensing BJ, Abizaid AS, Tanajura LF et al. Sustained suppression of neointimal proliferation by sirolimus-eluting stents: One-year angiographic and intravascular ultrasound follow-up. Circulation 2001;104:2007-11
13. Lemos PA, Serruys PW, van Domburg RT, Saia F, Arampatzis CA, Hoye A et al. Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the "real world": The Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry. Circulation 2004;109:190-5
14. Morice MC, Serruys PW, Barragan P, Bode C, Van Es GA, Stoll HP et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346:1773-80
15. Sabate M, Jimenez-Quevedo P, Angiolillo DJ, Gomez-Hospital JA, Alfonso F, Hernandez-Antolin R et al; DIABETES Investigators. Randomized comparison of sirolimus-eluting stent versus standard stent for percutaneous coronary revascularization in diabetic patients: The diabetes and sirolimus-eluting stent (DIABETES) trial. Circulation. 2005;112:2175-83
16. Daemen J1, Wenaweser P, Tsuchida K, Abrecht L, Vaina S, Morger C et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: Data from a large two-institutional cohort study. Lancet 2007;369:667-78
17. Wenaweser P1, Daemen J, Zwahlen M, van Domburg R, Juni P, Vai-na S et al. Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice:4-year results from a large 2-institutional cohort study. J Am Coll Cardiol 2008;52:1134-40
18. Serruys PW1, Onuma Y, Garg S, Vranckx P, De Bruyne B, Morice MC et al. ARTS II Investigators:5-year clinical outcomes of the ARTS II (Arterial Revascularization Therapies Study II) of the sirolimus-eluting stent in the treatment of patients with multivessel de novo coronary artery lesions. J Am Coll Cardiol 2010;55:1093-101
19. Hofma SH1, van der Giessen WJ, van Dalen BM, Lemos PA, Mc-Fadden EP, Sianos G et al. Indication of long-term endothelial dysfunction after sirolimus-eluting stent implantation. Eur Heart J 2006;27:166-70
20. Togni M, Windecker S, Cocchia R, Wenaweser P, Cook S, Billinger M et al. Sirolimus-eluting stents associated with paradoxic coronary vasoconstriction. J Am Coll Cardiol 2005;46:231-36
21. Camenzind E, Steg PG, Wijns W. Stent thrombosis late after implantation of irst-generation drug-eluting stents: A cause for concern. Circulation 2007;115:1440-55
22. Pisterer M1, Brunner-La Rocca HP, Buser PT, Rickenbacher P, Hunziker P, Mueller C et al. Late clinical events after clopidogrel discontinuation may limit the beneit of drug-eluting stents: An observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol 2006;48:2584-91
23. Lagerqvist B, James SK, Stenestrand U, Lindback J, Nilsson T, Wallentin L. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 2007;356:1009-19
24. Park DW, Park SW, Lee SW, Kim YH, Lee CW, Hong MK et al. Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up. Am J Cardiol 2006;98:352-56
25. Eisenstein EL, Leon MB, Kandzari DE, Mauri L, Edwards R, Kong DF et al; ENDEAVOR III Investigators. Long-term clinical and economic analysis of the Endeavor zotarolimus-eluting stent versus the cypher sirolimus-eluting stent:3-year results from the ENDEAVOR III trial (Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions). JACC Cardiovasc Interv 2009;2:1199-207
26. Leon MB, Kandzari DE, Eisenstein EL, Anstrom KJ, Mauri L, Cutlip DE et al. ENDEAVOR IV Investigators. Late safety, eficacy, and cost-effectiveness of a zotarolimus-eluting stent compared with a paclitaxel-eluting stent in patients with de novo coronary lesions:2-year follow-up from the ENDEAVOR IV trial (Randomized, Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Taxus Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions). JACC Cardiovasc Interv 2009;2:1208-18
27. Sabate M, Cequier A, Iniguez A, Serra A, Hernandez-Antolin R, Mainar V et al. Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION):1 year results of a randomised controlled trial. Lancet 2012;380:1482-90
28. Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J et al. SPIRIT III Investigators. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: Two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial. Circulation 2009;119:680-6
29. Brener SJ, Kereiakes DJ, Simonton CA, Rizvi A, Newman W, Mastali K et al. Everolimus-eluting stents in patients undergoing percutaneous coronary intervention: Inal 3-year results of the Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Subjects With de Novo Native Coronary Artery Lesions trial. Am Heart J 2013;166:1035-42
30. Windecker S, Serruys PW, Wandel S, Buszman P, Trznadel S, LinkeA et al. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): A randomised non- inferiority trial. Lancet 2008;372:1163-73
31. Stefanini GG, Byrne RA, Serruys PW, de Waha A, Meier B, Massberg S et al. Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: A pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials. Eur Heart J 2012;33:1214-22
32. Christiansen EH, Jensen LO, Thayssen P, Tilsted HH, Krusell LR, Hansen KN et al. Biolimus-eluting biodegradable polymer- coated stent versus durable polymer-coated sirolimus-eluting stent in unselected patients receiving percutaneous coronary intervention (SORT OUT V): A randomised non-inferiority trial. Lancet 2013;381:661-9
33. Zhang Y, Tian N, Dong S, Ye F, Li M, Bourantas CV et al. Impact of biodegradable versus durable polymer drug-eluting stents on clinical outcomes in patients with coronary artery disease: A metaanalysis of 15 randomized trials. Chin Med J. 2014;127:2159-66
34. Pilgrim T, Heg D, Rofi M, Tuller D, Muller O, Vuilliomenet A, Cook S et al. Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent for percutaneous coronary revascularisation (BIOSCIENCE): A randomised, single-blind, non-inferiority trial. Lancet 2014 [Epub ahead of print]
35. Nobuyoshi M, Kimura T, Nosaka H, Mioka S, Ueno K, Yokoi H et al. Restenosis after successful percutaneous trans-luminal coronary angioplasty: Serial angiographic follow-up of 229 patients. J Am Coll Cardiol 1988;12:616-23
36. Kaltenbach M, Kober G, Scherer D, Vallbracht C. Recurrence rate after successful coronary angioplasty. Eur Heart J 1985;6:276-81
37. Kimura T, Kaburagi S, Tamura T, Yokoi H, Nakagawa Y, Yokoi H et al. Remodeling of human coronary arteries undergoing coronary angioplasty or atherectomy. Circulation 1997;96:475-83
38. Hoffmann R, Mintz GS, Dussaillant GR, Popma JJ, Pichard AD, Satler LF et al. Patterns and mechanisms of in-stent restenosis: A serial intravascular ultrasound study. Circulation 1996;94:1247-54
39. Luo H, Nishioka T, Eigler NL, Forrester JS, Fishbein MC, Berglund H et al. Coronary artery restenosis after balloon angioplasty in humans is associated with circumferential coronary constriction. Arterioscler Thromb Vasc Biol 1996;16:1393-8
40. Brugaletta S, Garcia-Garcia HM, Onuma Y, Serruys PW. Everolimus-eluting ABSORB bioresorbable vascular scaffold: Present and future perspectives. Expert Rev Med Devices 2012;9:327-38
41. Babalik E, Gulbaran M, Gurmen T, Ozturk S. Fracture of popliteal artery stents. Circ J 2003;67:643-5
42. Eggebrecht H, Rodermann J, Hunold P, Schmermund A, Bose D, Haude M et al. Images in cardiovascular medicine: Novel magnetic resonance-compatible coronary stent: The absorbable magnesiumalloy stent. Circulation 2005;112:e303-e4
43. Di Mario C, Borgia F. Assimilating the current clinical data of fully bioabsorbable stents. Eurointervention 2009;5:F103-F8
44. Serruys PW, Chevalier B, Dudek D, Cequier A, Carrie D, Iniguez A et al. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): An interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial. Lancet 2014 [In press]
45. Vorpahl M, Finn AV, Nakano M, Virmani R. The bioabsorption process: Tissue and cellular mechanisms and outcomes. EuroIntervention 2009;5(Suppl F):F28-F3
46. Gogas BD, Radu M, Onuma Y, Perkins L, Powers JC, Gomez-Lara J et al. Evaluation with in vivo optical coherence tomography and histology of the vascular effects of the everolimus-eluting bioresorbable vascular scaffold at two years following implantation in a healthy porcine coronary artery model: Implications of pilot results for future pre-clinical studies. Int J Cardiovasc Imaging 2012;28:499-511
47. Onuma Y, Serruys PW, Perkins LE, Okamura T, Gonzalo N, Garcia-Garcia HM et al. Intracoronary optical coherence tomography and histology at 1 month and 2, 3, and 4 years after implantation of everolimus-eluting bioresorbable vascular scaffolds in a porcine coronary artery model: An attempt to decipher the human optical coherence tomography images in the ABSORB trial. Circulation 2010;122:2288-300
48. Serruys PW, Onuma Y, Dudek D, Smits PC, Koolen J, Chevalier B et al. Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis 12-month clinical and imaging outcomes. J Am Coll Cardiol 2011;58:1578-88
49. Brugaletta S, Heo JH, Garcia-Garcia HM, Farooq V, van Geuns RJ, de Bruyne B et al. Endothelial-dependent vasomotion in a coronary segment treated by ABSORB everolimus-eluting bioresorbable vascular scaffold system is related to plaque composition at the time of bioresorption of the polymer: Indirect inding of vascular reparative therapy? Eur Heart J. 2012;33:1325-33
50. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315-23
51. Shin DI, Kim PJ, Seung KB, Kim DB, Kim MJ, Chang K et al. Drug-eluting stent implantation could be associated with long-term coronary endothelial dysfunction. Int Heart J 2007;48:553-67
52. Rusinaru D, Vrolix M, Verheye S, Chowdhary S, Schoors D, Di Mario C et al. Bioabsorbable polymer-coated sirolimus-eluting stent implantation preserves coronary vasomotion: A DESSOLVE II trial sub-study. Catheter Cardiovasc Interv 2014 [In press]
53. Brugaletta S, Radu MD, Garcia-Garcia HM, Heo JH, Farooq V, Girasis C et al. Circumferential evaluation of the neointima by optical coherence tomography after ABSORB bioresorbable vascular scaffold implantation: Can the scaffold cap the plaque. Atherosclerosis 2012;221:106-12
54. Bourantas CV, Papafaklis MI, Kotsia A, Farooq V, Muramatsu T, Gomez-Lara J et al. Effect of the endothelial shear stress patterns on neointimal proliferation following drug-eluting bioresorbable vascular scaffold implantation: An optical coherence tomography study. JACC Cardiovasc Interv 2014;7:315-24
55. Nakatani S, Onuma Y, Ishibashi Y, Eggermont J, Zhang YJ, Campos CM et al; ABSORB Cohort B investigators. Temporal evolution of strut light intensity after implantation of bioresorbable polymeric intracoronary scaffolds in the ABSORB cohort B trial-an application of a new quantitative method based on optical coherence tomography. Circ J 2014;78:1873-81
56. Simsek C, Magro M, Onuma Y, Boersma E, Smits P, Dorange C et al. Procedural and clinical outcomes of the Absorb everolimuseluting bioresorbable vascular scaffold: One-month results of the Bioresorbable vascular Scaffold Evaluated At Rotterdam Cardiology Hospitals (B-SEARCH). EuroIntervention 2013;10:236-40
57. Fernandez-Rodriguez D, Brugaletta S, Otsuki S, Sabate M. Acute absorb bioresorbable vascular scaffold thrombosis in ST-segment elevation myocardial infarction: To stent or not to stent. EuroIntervention 2014;22;10:600
58. Capodanno D, Gori T, Nef H, Latib A, Mehilli J, Lesiak M et al. Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: Early and midterm outcomes from the European multicentre GHOST-EU registry. EuroIntervention 2014 [In press]
59. Okamura T, Serruys PW, Regar E. Cardiovascular lashlight. The fate of bioresorbable struts located at a side branch ostium: Serial three-dimensional optical coherence tomography assessment. Eur Heart J 2010;31:2179
60. Gogas BD, van Geuns RJ, Farooq V. Three-dimension- al reconstruction of the post-dilated ABSORB everolimus- eluting bioresorbable vascular scaffold in a true bifurcation lesion for low restoration. JACC Cardiovasc Interv 2011;4:1149-50
61. van Geuns RJ, Gogas BD, Farooq V, Regar E, Serruys PW. 3-Dimensional reconstruction of a bifurcation lesion with double wire after implantation of a second generation everolimus-eluting bioresorbable vascular scaffold. Int J Car diol 2011;153:e43-5
62. Fernandez D, Brugaletta S, Martin-Yuste V, Regueiro A, de Mingo A, Santos A et al. First experience of a bioresorbable vascular scaffold implantation in left main stenosis. Int J Cardiol 2013;168:1566-8
63. Muramatsu T, Onuma Y, Garcia-Garcia HM, Farooq V, Bourantas CV, Morel MA et al.; ABSORB-EXTEND Investigators. Incidence and short-term clinical outcomes of small side branch occlusion after implantation of an everolimus-eluting bioresorbable vascular scaffold: An interim report of 435 patients in the ABSORB-EXTEND single-arm trial in comparison with an everolimus-eluting metallic stent in the SPIRIT irst and II trials. JACC Cardiovasc Interv 2013;6:247-57
64. Davik V, Colombo A. The absorb bioresorbable vascular scaffold in coronary bifurcations: Insights from bench testing. JACC Cardiovasc Interv 2014;7:81-8
65. Attizzani GF, Ohno Y, Capodanno D, Francaviglia B, Grasso C, Sgroi C et al. New insights on acute expansion and longitudinal elongation of bioresorbable vascular scaffolds in vivo and at bench test: A note of caution on reliance to compliance charts and nominal length. Catheter Cardiovasc Interv 2014 [In press]
66. Brown AJ, McCormick LM, Braganza DM, Bennett MR, Hoole SP, West NE. Expansion and malapposition characteristics after bioresorbable vascular scaffold implantation. Catheter Cardiovasc Interv 2014;84:37-45
67. Tanimoto S, Serruys PW, Thuesen L, Dudek D, de Bruyne B, Chevalier B et al. Comparison of in vivo acute stent recoil between the bioabsorbable everolimus-eluting coronary stent and the everolimus-eluting cobalt chromium coronary stent: Insights from the ABSORB and SPIRIT trials. Catheter Cardiovasc Interv 2007;70:515-23
68. Onuma Y, Serruys PW, Gomez J, de Bruyne B, Dudek D, Thuesen L et al.; ABSORB Cohort A and B investigators. Comparison of in vivo acute stent recoil between the bioresorbable everolimuseluting coronary scaffolds (revision 1.0 and 1.1) and the metallic everolimus-eluting stent. Catheter Cardiovasc Interv 2011;7 8:3-12
69. Ishibashi Y, Onuma Y, Muramatsu T, Nakatani S, Iqbal J, Garcia-Garcia HM et al.. ABSORB EXTEND Investigators. Lessons learned from acute and late scaffold failures in the ABSORB EXTEND trial. EuroIntervention 2014;10:449-57
70. Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS); European Association for Percutaneous Cardiovascular Interventions (EAPCI), Wijns W, Kolh P, Danchin N, Di Mario C, Falk V, Folliguet T et al. Guidelines on myocardial revascularization. Eur Heart J 2010;31:2501-55
71. Spaulding C, Henry P, Teiger E, Beatt K, Bramucci E, Carrie D et al. Sirolimus-eluting versus uncoated stents in acute myocardial infarction. N Engl J Med 2006;355:1093-104
72. Stone GW, Lansky AJ, Pocock SJ, Gersh BJ, Dangas G, Wong SC et al. Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction. N Engl J Med 2009;360:1946-59
73. Brar SS, Leon MB, Stone GW, Mehran R, Moses JW, Brar SK et al. Use of drug-eluting stents in acute myocardial infarction: A systematic review and meta-analysis. J Am Coll Cardiol 2009;53:1677-89
74. Raber L, Kelbak H, Ostojic M, Baumbach A, Heg D, Tuller D et al. Investigators CAT. Effect of biolimus-eluting stents with biodegradable polymer vs. bare-metal stents on cardiovascular events among patients with acute myocardial infarction: The COMFORTABLE AMI randomized trial. JAMA 2012;308:777-87
75. Sabate M, Brugaletta S, Cequier A, Iniguez A, Serra A, Hernadez-Antolin R et al. The EXAMINATION trial (Everolimus-Eluting Stents Versus Bare-Metal Stents in ST-Segment Elevation Myocardial Infarction):2-year results from a multicenter randomized controlled trial. JACC Cardiovasc Interv 2014;7:64-71
76. Finn AV, Joner M, Nakazawa G, Kolodgie F, Newell J, John MC et al. Pathological correlates of late drug-eluting stent thrombosis: Strut coverage as a marker of endothelialization. Circulation 2007;115:2435-41
77. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E et al. Pathology of drug-eluting stents in humans: Delayed healing and late thrombotic risk. J Am Coll Cardiol 2006;48:193-202
78. Hong MK, Mintz GS, Lee CW, Kim YH, Lee SW, Song JM et al. Incidence, mechanism, predictors, and long-term prognosis of late stent malapposition after bare-metal stent implantation. Circulation 2004;109:881-6
79. Hong MK, Mintz GS, Lee CW, Park DW, Park KM, Lee BK et al. Late stent malapposition after drug-eluting stent implantation: An intravascular ultrasound analysis with long-term follow-up. Circulation 2006;113:414-9
80. Gomez O, Regueiro A, Santos A, Otsuki S, Scalone G, Fernandez-Rodriguez D et al. Recanalized Thrombus Treated With Bioresorbable Vascular Scaffold.Insights From Optical Coherence Tomography. JACC Cardiovasc Interv 2014 [In press]
81. Diletti R, Karanasos A, Muramatsu T, Nakatani S, Van Mieghem NM, Onuma Y et al. Everolimus-eluting bioresorbable vascular scaffolds for treatment of patients presenting with ST-segment elevation myocardial infarction: BVS STEMI irst study. Eur Heart J 2014;35:777-86
82. Kočka V1, Maly M, Toušek P, Buděšinsky T, Lisa L, Prodanov P et al. Bioresorbable vascular scaffolds in acute ST-segment elevation myocardial infarction: A prospective multicentre study 'Prague 19'. Eur Heart J 2014 [In press]
83. Dudek D. POLAR ACS:1-year follow-up - EAPCI 2014, Paris May 20-23
84. Gori T, Schulz E, Hink U, Wenzel P, Post F, Jabs A et al. Early outcome after implantation of Absorb bioresorbable drug-eluting scaffolds in patients with acute coronary syndromes. EuroIntervention 2014;9:1036-41
85. Serruys PW, Sabate M, Windecker S. Comparison of the ABSORBTM Everolimus Eluting Bioresorbable Vascular Scaffold System With a Drug- Eluting Metal Stent (XienceTM) in Acute STElevation Myocardial Infarction. NCT01986803
86. Wijns W, Vrolix M, Verheye S, Schoors D, Slagboom T, Gosselink M et al. Randomised study of a bioabsorbable polymer-coated sirolimus-eluting stent: Results of the DESSOLVE II trial. EuroIntervention 2014 [Epub ahead of print]
87. Granada JF. Feasibility Study of the Amaranth Medical FORTITUDE Bioresorbable Drug-Eluting Coronary Stent (MEND II). NCT02189499
88. Haude M, Neuss SK. First in man study of the DREAMS 2nd Generation Drug Eluting Absorbable Metal Scaffold (BIOSOLVE-II); NCT01960504
89. Hofma SH van der Giessen WJ, van Dalen BM, Lemos PA, Mc-Fadden EP, Sianos G et al. Indication of long-term endothelial dysfunction after sirolimus-eluting stent implantation. Eur Heart J 2006;27:166-70
90. Cook S. EVERBIO II: Everolimus-Eluting Bioresorbable Scaffold vs. Everolimus-Eluting and Biolimus-Eluting Metallic Stents in CAD Patients. TCT 2014, Washington DC September 13-17